Structure Therapeutics Inc: H.C. Wainwright cuts target price to $70 from $100

On June 11, 2026, H.C. Wainwright revised its price target for Structure Therapeutics Inc. (NASDAQ:GPCR), lowering it to $70 from a previous $100, while maintaining a Buy rating on the shares. This adjustment reflects a reassessment of the company’s valuation in light of evolving market dynamics and industry benchmarks. The firm cited key factors in its decision.

Structure Therapeutics, a clinical-stage biopharmaceutical company, continues to develop novel oral small-molecule therapeutics for chronic diseases with significant unmet medical needs. Earlier in the year, multiple analysts had raised their price targets for the company, citing strong Phase 2b data for its lead candidate, aleniglipron, and the potential for M&A activity. However, the latest downgrade by H.C. Wainwright suggests a more cautious outlook amid shifting investor sentiment and regulatory clarity in the biopharma sector.

Despite the reduced price target, the firm still views Structure Therapeutics as a compelling investment opportunity, particularly given its oral GLP-1 category leadership. Investors are advised to monitor upcoming developments in the company’s pipeline and broader industry trends for further guidance.